A
Price
$106.33
Change
+$1.33 (+1.27%)
Updated
Apr 24, 03:54 PM (EDT)
Capitalization
42.66B
34 days until earnings call
RGEN
Price
$145.14
Change
+$3.74 (+2.64%)
Updated
Apr 24, 02:46 PM (EDT)
Capitalization
10.26B
5 days until earnings call
Ad is loading...

A vs RGEN

Header iconA vs RGEN Comparison
Open Charts A vs RGENBanner chart's image
Agilent Technologies
Price$106.33
Change+$1.33 (+1.27%)
Volume$1.62K
Capitalization42.66B
Repligen
Price$145.14
Change+$3.74 (+2.64%)
Volume$517
Capitalization10.26B
A vs RGEN Comparison Chart
Loading...
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
A vs. RGEN commentary
Apr 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a StrongBuy and RGEN is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 24, 2025
Stock price -- (A: $105.00 vs. RGEN: $141.40)
Brand notoriety: A and RGEN are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: A: 95% vs. RGEN: 71%
Market capitalization -- A: $42.66B vs. RGEN: $10.26B
A [@Medical Specialties] is valued at $42.66B. RGEN’s [@Medical Specialties] market capitalization is $10.26B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

A’s FA Score shows that 1 FA rating(s) are green whileRGEN’s FA Score has 1 green FA rating(s).

  • A’s FA Score: 1 green, 4 red.
  • RGEN’s FA Score: 1 green, 4 red.
According to our system of comparison, A is a better buy in the long-term than RGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

A’s TA Score shows that 6 TA indicator(s) are bullish while RGEN’s TA Score has 5 bullish TA indicator(s).

  • A’s TA Score: 6 bullish, 3 bearish.
  • RGEN’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, A is a better buy in the short-term than RGEN.

Price Growth

A (@Medical Specialties) experienced а +2.24% price change this week, while RGEN (@Medical Specialties) price change was +7.04% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +4.08%. For the same industry, the average monthly price growth was -6.75%, and the average quarterly price growth was -2.65%.

Reported Earning Dates

A is expected to report earnings on May 28, 2025.

RGEN is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Medical Specialties (+4.08% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
A($42.7B) has a higher market cap than RGEN($10.3B). RGEN has higher P/E ratio than A: RGEN (247.52) vs A (34.82). RGEN YTD gains are higher at: -1.765 vs. A (-21.674). A has higher annual earnings (EBITDA): 1.69B vs. RGEN (134M). RGEN has less debt than A: RGEN (712M) vs A (2.56B). A has higher revenues than RGEN: A (6.74B) vs RGEN (639M).
ARGENA / RGEN
Capitalization42.7B10.3B415%
EBITDA1.69B134M1,261%
Gain YTD-21.674-1.7651,228%
P/E Ratio34.82247.5214%
Revenue6.74B639M1,054%
Total CashN/A751M-
Total Debt2.56B712M359%
FUNDAMENTALS RATINGS
A vs RGEN: Fundamental Ratings
A
RGEN
OUTLOOK RATING
1..100
812
VALUATION
overvalued / fair valued / undervalued
1..100
17
Undervalued
95
Overvalued
PROFIT vs RISK RATING
1..100
5976
SMR RATING
1..100
4490
PRICE GROWTH RATING
1..100
6558
P/E GROWTH RATING
1..100
782
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

A's Valuation (17) in the Biotechnology industry is significantly better than the same rating for RGEN (95). This means that A’s stock grew significantly faster than RGEN’s over the last 12 months.

A's Profit vs Risk Rating (59) in the Biotechnology industry is in the same range as RGEN (76). This means that A’s stock grew similarly to RGEN’s over the last 12 months.

A's SMR Rating (44) in the Biotechnology industry is somewhat better than the same rating for RGEN (90). This means that A’s stock grew somewhat faster than RGEN’s over the last 12 months.

RGEN's Price Growth Rating (58) in the Biotechnology industry is in the same range as A (65). This means that RGEN’s stock grew similarly to A’s over the last 12 months.

RGEN's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for A (78). This means that RGEN’s stock grew significantly faster than A’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARGEN
RSI
ODDS (%)
Bullish Trend 2 days ago
58%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
60%
Bearish Trend 2 days ago
72%
Momentum
ODDS (%)
Bullish Trend 2 days ago
63%
Bullish Trend 2 days ago
71%
MACD
ODDS (%)
Bullish Trend 2 days ago
67%
Bullish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
64%
Bullish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
63%
Bullish Trend 2 days ago
73%
Advances
ODDS (%)
Bullish Trend 2 days ago
62%
Bullish Trend 2 days ago
75%
Declines
ODDS (%)
Bearish Trend 4 days ago
60%
Bearish Trend 21 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
63%
Bullish Trend 2 days ago
67%
Aroon
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
77%
View a ticker or compare two or three
Ad is loading...
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MVV51.831.25
+2.47%
ProShares Ultra MidCap400
BRNY38.600.80
+2.10%
Burney U.S. Factor Rotation ETF
ROAM23.400.15
+0.65%
Hartford Multifactor Emerging Mkts ETF
USMV90.370.34
+0.38%
iShares MSCI USA Min Vol Factor ETF
FREL26.320.05
+0.19%
Fidelity MSCI Real Estate ETF

RGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGEN has been loosely correlated with DHR. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if RGEN jumps, then DHR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGEN
1D Price
Change %
RGEN100%
+1.78%
DHR - RGEN
66%
Loosely correlated
+2.21%
A - RGEN
60%
Loosely correlated
+2.13%
BIO - RGEN
57%
Loosely correlated
+1.58%
TMO - RGEN
56%
Loosely correlated
-0.71%
BLFS - RGEN
55%
Loosely correlated
+11.19%
More